CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Authors: Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, Stephen Gottschalk
Journal: Molecular Therapy (2020)

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to its success for hematological malignancies in clinical studies leading to the US Food and Drug Administration (FDA) approval of three CD19-targeted CAR T cell products. In contrast, the clinical experience with CAR T cell therapy for solid tumors and brain tumors has been less encouraging, with only a few patients achieving complete responses. Clinical and preclinical studies have identified multiple "roadblocks," including (1) a limited array of targetable antigens and heterogeneous antigen expression, (2) limited T cell fitness and survival before reaching tumor sites, (3) an inability of T cells to efficiently traffic to tumor sites and penetrate physical barriers, and (4) an immunosuppressive tumor microenvironment. Herein, we review these challenges and discuss strategies that investigators have taken to improve the effector function of CAR T cells for the adoptive immunotherapy of solid tumors. Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to its success for hematological malignancies in clinical studies leading to the US Food and Drug Administration (FDA) approval of three CD19-targeted CAR T cell products. In contrast, the clinical experience with CAR T cell therapy for solid tumors and brain tumors has been less encouraging, with only a few patients achieving complete responses. Clinical and preclinical studies have identified multiple "roadblocks," including (1) a limited array of targetable antigens and heterogeneous antigen expression, (2) limited T cell fitness and survival before reaching tumor sites, (3) an inability of T cells to efficiently traffic to tumor sites and penetrate physical barriers, and (4) an immunosuppressive tumor microenvironment. Herein, we review these challenges and discuss strategies that investigators have taken to improve the effector function of CAR T cells for the adoptive immunotherapy of solid tumors. Adoptive cell therapies utilizing T cells expressing chimeric antigen receptors (CARs) have been propelled to the forefront of experimental cell therapies due to their clinical success for hematological malignancies targeting a range of antigens, including CD19, CD22, CD30, kappa, and B cell maturation antigen (BCMA).1Porter D.L. Levine B.L. Kalos M. Bagg A. June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N. Engl. J. Med. 2011; 365: 725-733Crossref PubMed Scopus (2158) Google Scholar, 2Grupp S.A. Kalos M. Barrett D. Aplenc R. Porter D.L. Rheingold S.R. Teachey D.T. Chew A. Hauck B. Wright J.F. et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N. Engl. J. Med. 2013; 368: 1509-1518Crossref PubMed Scopus (1949) Google Scholar, 3Maude S.L. Frey N. Shaw P.A. Aplenc R. Barrett D.M. Bunin N.J. Chew A. Gonzalez V.E. Zheng Z. Lacey S.F. et al.Chimeric antigen receptor T cells for sustained remissions in leukemia.N. Engl. J. Med. 2014; 371: 1507-1517Crossref PubMed Scopus (2496) Google Scholar, 4Fry T.J. Shah N.N. Orentas R.J. Stetler-Stevenson M. Yuan C.M. Ramakrishna S. Wolters P. Martin S. Delbrook C. Yates B. et al.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat. Med. 2018; 24: 20-28Crossref PubMed Scopus (399) Google Scholar, 5Gardner R.A. Finney O. Annesley C. Brakke H. Summers C. Leger K. Bleakley M. Brown C. Mgebroff S. Kelly-Spratt K.S. et al.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.Blood. 2017; 129: 3322-3331Crossref PubMed Scopus (11) Google Scholar, 6Ramos C.A. Grover N.S. Beaven A.W. Lulla P.D. Wu M.F. Ivanova A. Wang T. Shea T.C. Rooney C.M. Dittus C. et al.Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma.J. Clin. Oncol. 2020; (Published online July 23, 2020. 10.1200/JCO.20.01342)Crossref Google Scholar, 7Ramos C.A. Savoldo B. Torrano V. Ballard B. Zhang H. Dakhova O. Liu E. Carrum G. Kamble R.T. Gee A.P. et al.Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.J. Clin. Invest. 2016; 126: 2588-2596Crossref PubMed Scopus (134) Google Scholar, 8Raje N. Berdeja J. Lin Y. Siegel D. Jagannath S. Madduri D. Liedtke M. Rosenblatt J. Maus M.V. Turka A. et al.Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.N. Engl. J. Med. 2019; 380: 1726-1737Crossref PubMed Scopus (249) Google Scholar, 9Turtle C.J. Hanafi L.A. Berger C. Hudecek M. Pender B. Robinson E. Hawkins R. Chaney C. Cherian S. Chen X. et al.Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci. Transl. Med. 2016; 8: 355ra116Crossref PubMed Scopus (421) Google Scholar, 10Kochenderfer J.N. Somerville R.P.T. Lu T. Yang J.C. Sherry R.M. Feldman S.A. McIntyre L. Bot A. Rossi J. Lam N. Rosenberg S.A. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy.Mol. Ther. 2017; 25: 2245-2253Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar The landscape of CAR T cell therapies for hematological malignancies, including successes and challenges, has been the subject of multiple recent reviews.11Holstein S.A. Lunning M.A. CAR T-cell therapy in hematologic malignancies: a voyage in progress.Clin. Pharmacol. Ther. 2020; 107: 112-122Crossref PubMed Scopus (0) Google Scholar, 12Boyiadzis M.M. Dhodapkar M.V. Brentjens R.J. Kochenderfer J.N. Neelapu S.S. Maus M.V. Porter D.L. Maloney D.G. Grupp S.A. Mackall C.L. et al.Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.J. Immunother. Cancer. 2018; 6: 137Crossref PubMed Scopus (48) Google Scholar, 13Majzner R.G. Mackall C.L. Clinical lessons learned from the first leg of the CAR T cell journey.Nat. Med. 2019; 25: 1341-1355Crossref PubMed Scopus (58) Google Scholar We therefore do not discuss these in detail, except for highlighting the "lessons learned" as they relate to targeting solid tumors, including brain tumors. First, CAR T cells can eradicate chemorefractory cancer cells regardless of their underlying oncogenic driver mutations; second, lymphodepleting chemotherapy is at present a sine qua non to enable expansion and persistence of infused CAR T cells; third, inclusion of at least one co-stimulatory signaling domain in the CAR is critical for its success; fourth: antigen loss variants have emerged as one mechanism of therapeutic failure, even for antigens that are highly and homogeneously expressed such as CD19; and fifth, CAR T cells can induce significant side effects, including cytokine release syndrome (CRS) and neurotoxicity.11Holstein S.A. Lunning M.A. CAR T-cell therapy in hematologic malignancies: a voyage in progress.Clin. Pharmacol. Ther. 2020; 107: 112-122Crossref PubMed Scopus (0) Google Scholar, 12Boyiadzis M.M. Dhodapkar M.V. Brentjens R.J. Kochenderfer J.N. Neelapu S.S. Maus M.V. Porter D.L. Maloney D.G. Grupp S.A. Mackall C.L. et al.Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.J. Immunother. Cancer. 2018; 6: 137Crossref PubMed Scopus (48) Google Scholar, 13Majzner R.G. Mackall C.L. Clinical lessons learned from the first leg of the CAR T cell journey.Nat. Med. 2019; 25: 1341-1355Crossref PubMed Scopus (58) Google Scholar, 14Neelapu S.S. Tummala S. Kebriaei P. Wierda W. Locke F.L. Lin Y. Jain N. Daver N. Gulbis A.M. Adkins S. et al.Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit "ALL".Nat. Rev. Clin. Oncol. 2018; 15: 218Crossref PubMed Scopus (0) Google Scholar, 15Lee D.W. Santomasso B.D. Locke F.L. Ghobadi A. Turtle C.J. Brudno J.N. Maus M.V. Park J.H. Mead E. Pavletic S. et al.ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol. Blood Marrow Transplant. 2019; 25: 625-638Abstract Full Text Full Text PDF PubMed Scopus (307) Google Scholar In contrast to CAR T cell therapy for hematological malignancies, CAR T cell therapies for solid tumors, including brain tumors, have shown limited antitumor activity in early phase clinical testing despite targeting a variety of target antigens and tumor types.16Goff S.L. Morgan R.A. Yang J.C. Sherry R.M. Robbins P.F. Restifo N.P. Feldman S.A. Lu Y.C. Lu L. Zheng Z. et al.Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma.J. Immunother. 2019; 42: 126-135Crossref PubMed Scopus (0) Google Scholar, 17O'Rourke D.M. Nasrallah M.P. Desai A. Melenhorst J.J. Mansfield K. Morrissette J.J.D. Martinez-Lage M. Brem S. Maloney E. Shen A. et al.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Sci. Transl. Med. 2017; 9 (eaaa0984)PubMed Google Scholar, 18Morgan R.A. Yang J.C. Kitano M. Dudley M.E. Laurencot C.M. Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Mol. Ther. 2010; 18: 843-851Abstract Full Text Full Text PDF PubMed Scopus (1312) Google Scholar, 19Lamers C.H. Sleijfer S. Vulto A.G. Kruit W.H. Kliffen M. Debets R. Gratama J.W. Stoter G. Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.J. Clin. Oncol. 2006; 24: e20-e22Crossref PubMed Scopus (597) Google Scholar, 20Lamers C.H. Sleijfer S. van Steenbergen S. van Elzakker P. van Krimpen B. Groot C. Vulto A. den Bakker M. Oosterwijk E. Debets R. Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Mol. Ther. 2013; 21: 904-912Abstract Full Text Full Text PDF PubMed Scopus (359) Google Scholar, 21Kershaw M.H. Westwood J.A. Parker L.L. Wang G. Eshhar Z. Mavroukakis S.A. White D.E. Wunderlich J.R. Canevari S. Rogers-Freezer L. et al.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Clin. Cancer Res. 2006; 12: 6106-6115Crossref PubMed Scopus (733) Google Scholar, 22Brown C.E. Alizadeh D. Starr R. Weng L. Wagner J.R. Naranjo A. Ostberg J.R. Blanchard M.S. Kilpatrick J. Simpson J. et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy.N. Engl. J. Med. 2016; 375: 2561-2569Crossref PubMed Google Scholar, 23Ahmed N. Brawley V.S. Hegde M. Robertson C. Ghazi A. Gerken C. Liu E. Dakhova O. Ashoori A. Corder A. et al.Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma.J. Clin. Oncol. 2015; 33: 1688-1696Crossref PubMed Scopus (444) Google Scholar, 24Wang Y. Chen M. Wu Z. Tong C. Dai H. Guo Y. Liu Y. Huang J. Lv H. Luo C. et al.CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial.OncoImmunology. 2018; 7: e1440169Crossref PubMed Scopus (60) Google Scholar, 25Thistlethwaite F.C. Gilham D.E. Guest R.D. Rothwell D.G. Pillai M. Burt D.J. Byatte A.J. Kirillova N. Valle J.W. Sharma S.K. et al.The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.Cancer Immunol. Immunother. 2017; 66: 1425-1436Crossref PubMed Scopus (94) Google Scholar, 26Ahmed N. Brawley V. Hegde M. Bielamowicz K. Kalra M. Landi D. Robertson C. Gray T.L. Diouf O. Wakefield A. et al.HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial.JAMA Oncol. 2017; 3: 1094-1101Crossref PubMed Scopus (187) Google Scholar This therapeutic failure is most likely multifactorial and includes (1) CAR design and CAR T cell generation, (2) a limited array of targetable antigens and heterogeneous antigen expression (aka "antigen dilemma"), (3) limited T cell fitness, (4) inefficient homing to and penetration of solid tumors, and (5) the hostile tumor microenvironment (TME) (Figure 1).27Rafiq S. Hackett C.S. Brentjens R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat. Rev. Clin. Oncol. 2020; 17: 147-167Crossref PubMed Scopus (46) Google Scholar, 28Rodriguez-Garcia A. Palazon A. Noguera-Ortega E. Powell Jr., D.J. Guedan S. CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape.Front. Immunol. 2020; 11: 1109Crossref PubMed Scopus (0) Google Scholar, 29Schmidts A. Maus M.V. Making CAR T cells a solid option for solid tumors.Front. Immunol. 2018; 9: 2593Crossref PubMed Scopus (48) Google Scholar, 30Knochelmann H.M. Smith A.S. Dwyer C.J. Wyatt M.M. Mehrotra S. Paulos C.M. CAR T cells in solid tumors: blueprints for building effective therapies.Front. Immunol. 2018; 9: 1740Crossref PubMed Google Scholar Herein, we review CAR design, the current clinical experience with autologous CAR T cells for solid tumors, including brain tumors, and genetic approaches to overcome the aforementioned roadblocks. Since allogeneic CAR T cells are at present mainly explored for hematological malignancies in early phase clinical studies, we refer the interested reader to recently published reviews.31Depil S. Duchateau P. Grupp S.A. Mufti G. Poirot L. "Off-the-shelf" allogeneic CAR T cells: development and challenges.Nat. Rev. Drug Discov. 2020; 19: 185-199Crossref PubMed Scopus (47) Google Scholar,32Qasim W. Allogeneic CAR T cell therapies for leukemia.Am. J. Hematol. 2019; 94: S50-S54Crossref PubMed Scopus (10) Google Scholar We also do not review CRS and neurotoxicity since several recent reviews have covered this topic.14Neelapu S.S. Tummala S. Kebriaei P. Wierda W. Locke F.L. Lin Y. Jain N. Daver N. Gulbis A.M. Adkins S. et al.Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit "ALL".Nat. Rev. Clin. Oncol. 2018; 15: 218Crossref PubMed Scopus (0) Google Scholar,33Frey N. Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy.Biol. Blood Marrow Transplant. 2019; 25: e123-e127Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar CARs have a modular design that consists of an antigen-binding domain, most commonly a single-chain variable fragment (scFv) derived from a monoclonal antibody (mAb), a hinge and transmembrane domain, and an intracellular signaling domain.27Rafiq S. Hackett C.S. Brentjens R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat. Rev. Clin. Oncol. 2020; 17: 147-167Crossref PubMed Scopus (46) Google Scholar,34Kuwana Y. Asakura Y. Utsunomiya N. Nakanishi M. Arata Y. Itoh S. Nagase F. Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.Biochem. Biophys. Res. Commun. 1987; 149: 960-968Crossref PubMed Scopus (148) Google Scholar, 35Gross G. Waks T. Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proc. Natl. Acad. Sci. USA. 1989; 86: 10024-10028Crossref PubMed Scopus (724) Google Scholar, 36Eshhar Z. Waks T. Gross G. Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proc. Natl. Acad. Sci. USA. 1993; 90: 720-724Crossref PubMed Scopus (816) Google Scholar, 37June C.H. Sadelain M. Chimeric antigen receptor therapy.N. Engl. J. Med. 2018; 379: 64-73Crossref PubMed Scopus (436) Google Scholar, 38Dotti G. Gottschalk S. Savoldo B. Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells.Immunol. Rev. 2014; 257: 107-126Crossref PubMed Scopus (256) Google Scholar In addition to scFvs, natural ligands of receptors such as cytokines or peptides that bind cell surface molecules are also being explored as antigen-binding domains.22Brown C.E. Alizadeh D. Starr R. Weng L. Wagner J.R. Naranjo A. Ostberg J.R. Blanchard M.S. Kilpatrick J. Simpson J. et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy.N. Engl. J. Med. 2016; 375: 2561-2569Crossref PubMed Google Scholar,39Shaffer D.R. Savoldo B. Yi Z. Chow K.K. Kakarla S. Spencer D.M. Dotti G. Wu M.F. Liu H. Kenney S. Gottschalk S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.Blood. 2011; 117: 4304-4314Crossref PubMed Scopus (0) Google Scholar,40Davies D.M. Foster J. Van Der Stegen S.J. Parente-Pereira A.C. Chiapero-Stanke L. Delinassios G.J. Burbridge S.E. Kao V. Liu Z. Bosshard-Carter L. et al.Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.Mol. Med. 2012; 18: 565-576Crossref PubMed Scopus (54) Google Scholar While most CARs recognize epitopes of cell surface proteins in a major histocompatibility complex (MHC)-independent manner, scFvs have also been incorporated into CARs that recognize a peptide in the context of a human leukocyte antigen (HLA) molecule.41Ma Q. Garber H.R. Lu S. He H. Tallis E. Ding X. Sergeeva A. Wood M.S. Dotti G. Salvado B. et al.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.Cytotherapy. 2016; 18: 985-994Abstract Full Text Full Text PDF PubMed Google Scholar, 42Rafiq S. Purdon T.J. Daniyan A.F. Koneru M. Dao T. Liu C. Scheinberg D.A. Brentjens R.J. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen.Leukemia. 2017; 31: 1788-1797Crossref PubMed Scopus (0) Google Scholar, 43Maus M.V. Plotkin J. Jakka G. Stewart-Jones G. Rivière I. Merghoub T. Wolchok J. Renner C. Sadelain M. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.Mol. Ther. Oncolytics. 2017; 3: 1-9PubMed Google Scholar While this approach allows CAR T cells to recognize intracellular molecules, it renders target antigen recognition dependent on a particular HLA type, restricting its application to a subset of patients. In addition, CAR T cells become sensitive to decreased HLA expression and defects in the antigen processing pathway, with both pathways used by tumor cells to actively evade immune responses.44Töpfer K. Kempe S. Müller N. Schmitz M. Bachmann M. Cartellieri M. Schackert G. Temme A. Tumor evasion from T cell surveillance.J. Biomed. Biotechnol. 2011; 2011: 918471Crossref PubMed Scopus (94) Google Scholar First-generation CARs contained only a T cell activation domain, and the most commonly utilized domain is derived from CD3ζ.37June C.H. Sadelain M. Chimeric antigen receptor therapy.N. Engl. J. Med. 2018; 379: 64-73Crossref PubMed Scopus (436) Google Scholar,38Dotti G. Gottschalk S. Savoldo B. Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells.Immunol. Rev. 2014; 257: 107-126Crossref PubMed Scopus (256) Google Scholar Since optimal T cell activation also relies on co-stimulation, signaling domains from co-stimulatory molecules were included into CARs. Initial studies focused on domains derived from the canonical co-stimulatory molecules CD28 and 41BB.37June C.H. Sadelain M. Chimeric antigen receptor therapy.N. Engl. J. Med. 2018; 379: 64-73Crossref PubMed Scopus (436) Google Scholar,38Dotti G. Gottschalk S. Savoldo B. Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells.Immunol. Rev. 2014; 257: 107-126Crossref PubMed Scopus (256) Google Scholar Since then, signaling domains from a broad range of molecules have been explored, including OX40, CD27, and ICOS.37June C.H. Sadelain M. Chimeric antigen receptor therapy.N. Engl. J. Med. 2018; 379: 64-73Crossref PubMed Scopus (436) Google Scholar,45Rafiq S. Yeku O.O. Jackson H.J. Purdon T.J. van Leeuwen D.G. Drakes D.J. Song M. Miele M.M. Li Z. Wang P. et al.Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.Nat. Biotechnol. 2018; 36: 847-856Crossref PubMed Scopus (161) Google Scholar, 46Hombach A.A. Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.Int. J. Cancer. 2011; 129: 2935-2944Crossref PubMed Scopus (93) Google Scholar, 47Collinson-Pautz M.R. Chang W.C. Lu A. Khalil M. Crisostomo J.W. Lin P.Y. Mahendravada A. Shinners N.P. Brandt M.E. Zhang M. et al.Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.Leukemia. 2019; 33: 2195-2207Crossref PubMed Scopus (14) Google Scholar, 48Guedan S. Chen X. Madar A. Carpenito C. McGettigan S.E. Frigault M.J. Lee J. Posey Jr., A.D. Scholler J. Scholler N. et al.ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.Blood. 2014; 124: 1070-1080Crossref PubMed Scopus (162) Google Scholar, 49Nair S. Wang J.B. Tsao S.T. Liu Y. Zhu W. Slayton W.B. Moreb J.S. Dong L. Chang L.J. Functional improvement of chimeric antigen receptor through intrinsic interleukin-15Rα signaling.Curr. Gene Ther. 2019; 19: 40-53Crossref PubMed Scopus (7) Google Scholar CD28 and 41BB co-stimulation in the context of CAR T cells has been extensively studied, including detailed phosphoproteomic and single-cell RNA sequencing (RNA-seq) analyses.50Salter A.I. Ivey R.G. Kennedy J.J. Voillet V. Rajan A. Alderman E.J. Voytovich U.J. Lin C. Sommermeyer D. Liu L. et al.Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.Sci. Signal. 2018; 11: eaat6753Crossref PubMed Scopus (94) Google Scholar, 51Boroughs A.C. Larson R.C. Marjanovic N.D. Gosik K. Castano A.P. Porter C.B.M. Lorrey S.J. Ashenberg O. Jerby L. Hofree M. et al.A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq.Mol. Ther. 2020; (Published online July 25, 2020)https://doi.org/10.1016/j.ymthe.2020.07.023Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar, 52Xhangolli I. Dura B. Lee G. Kim D. Xiao Y. Fan R. Single-cell analysis of CAR-T cell activation reveals a mixed TH1/TH2 response independent of differentiation.Genomics Proteomics Bioinformatics. 2019; 17: 129-139Crossref PubMed Scopus (13) Google Scholar They activate different pathways within T cells, with CD28 signaling promoting glycolytic metabolism and an effector memory phenotype, in contrast to 41BB signaling, which induces oxidative metabolism and a central memory phenotype.53Kawalekar O.U. O' Connor R.S. Fraietta J.A. Guo L. McGettigan S.E. Posey Jr., A.D. Patel P.R. Guedan S. Scholler J. Keith B. et al.Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells.Immunity. 2016; 44: 712Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar Depending on the number of co-stimulatory molecules included in the CAR signaling domain, CARs are either designated second (one domain) or third (two domains) generation. In preclinical studies, the benefit of including two co-stimulatory molecules in CARs is model-dependent.54Quintarelli C. Orlando D. Boffa I. Guercio M. Polito V.A. Petretto A. Lavarello C. Sinibaldi M. Weber G. Del Bufalo F. et al.Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.OncoImmunology. 2018; 7: e1433518Crossref PubMed Scopus (37) Google Scholar,55Zhao Z. Condomines M. van der Stegen S.J.C. Perna F. Kloss C.C. Gunset G. Plotkin J. Sadelain M. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells.Cancer Cell. 2015; 28: 415-428Abstract Full Text Full Text PDF PubMed Scopus (288) Google Scholar Results of one clinical study, comparing CD28-CAR versus CD28.41BB-CAR T cells targeting CD19, suggest that third-generation CARs endow T cells with a greater ability to expand after infusion in humans.56Ramos C.A. Rouce R. Robertson C.S. Reyna A. Narala N. Vyas G. Mehta B. Zhang H. Dakhova O. Carrum G. et al.In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas.Mol. Ther. 2018; 26: 2727-2737Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar Optimizing CAR function remains a challenge since there is an intricate interplay between the functional (antigen recognition and signaling domains) and nonfunctional components (hinge and transmembrane domain) of CARs.57Guest R.D. Hawkins R.E. Kirillova N. Cheadle E.J. Arnold J. O'Neill A. Irlam J. Chester K.A. Kemshead J.T. Shaw D.M. et al.The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.J. Immunother. 2005; 28: 203-211Crossref PubMed Google Scholar,58Majzner R.G. Rietberg S.P. Sotillo E. Dong R. Vachharajani V.T. Labanieh L. Myklebust J.H. Kadapakkam M. Weber E.W. Tousley A.M. et al.Tuning the antigen density requirement for CAR T-cell activity.Cancer Discov. 2020; 10: 702-723Crossref PubMed Scopus (17) Google Scholar In addition, the location of the epitope within the targeted cell surface molecule determines CAR T cell activity.59Hudecek M. Lupo-Stanghellini M.T. Kosasih P.L. Sommermeyer D. Jensen M.C. Rader C. Riddell S.R. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.Clin. Cancer Res. 2013; 19: 3153-3164Crossref PubMed Scopus (246) Google Scholar For example, epitopes that are proximal to the plasma membrane induce greater CAR T cell activation than do distal epitopes.57Guest R.D. Hawkins R.E. Kirillova N. Cheadle E.J. Arnold J. O'Neill A. Irlam J. Chester K.A. Kemshead J.T. Shaw D.M. et al.The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.J. Immunother. 2005; 28: 203-211Crossref PubMed Google Scholar,59Hudecek M. Lupo-Stanghellini M.T. Kosasih P.L. Sommermeyer D. Jensen M.C. Rader C. Riddell S.R. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.Clin. Cancer Res. 2013; 19: 3153-3164Crossref PubMed Scopus (246) Google Scholar,60James S.E. Greenberg P.D. Jensen M.C. Lin Y. Wang J. Till B.G. Raubitschek A.A. Forman S.J. Press O.W. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.J. Immunol. 2008; 180: 7028-7038Crossref PubMed Scopus (126) Google Scholar Studies have also highlighted that too much CAR T cell activation is detrimental to T cell function. For example, CARs with two of three mutated immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3ζ chain endow CAR T cells with improved effector function.61Feucht J. Sun J. Eyquem J. Ho Y.J. Zhao Z. Leibold J. Dobrin A. Cabriolu A. Hamieh M. Sadelain M. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.Nat. Med. 2019; 25: 82-88Crossref PubMed Scopus (81) Google Scholar In addition, excessive CD28 co-stimulation has detrimental effects,62Wijewarnasuriya D. Bebernitz C. Lopez A.V. Rafiq S. Brentjens R.J. Excessive costimulation leads to dysfunction of adoptively transferred T cells.Cancer Immunol. Res. 2020; 8: 732-742Crossref PubMed Scopus (0) Google Scholar and mutations in the YMXM motif of CD28 that reduce its signaling activity improve T cell function.63Guedan S. Madar A. Casado-Medrano V. Shaw C. Wing A. Liu F. Young R.M. June C.H. Posey Jr., A.D. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.J. Clin. Invest. 2020; 130: 3087-3097Crossref PubMed Scopus (12) Google Scholar In addition to CAR signaling after activation, baseline (aka tonic) signaling determines CAR T cell activity.64Long A.H. Haso W.M. Shern J.F. Wanhainen K.M. Murgai M. Ingaramo M. Smith J.P. Walker A.J. Kohler M.E. Venkateshwara V.R. et al.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat. Med. 2015; 21: 581-590Crossref PubMed Scopus (528) Google Scholar,65Gomes-Silva D. Mukherjee M. Srinivasan M. Krenciute G. Dakhova O. Zheng Y. Cabral J.M.S. Rooney C.M. Orange J.S. Brenner M.K. Mamonkin M. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent.Cell Rep. 2017; 21: 17-26Abstract Full Text Full Text PDF PubMed Scopus (80) Google Scholar Recently, investigators have also focused on studying the immunological synapse that is formed between CAR T cells and target cells, and they have correlated synapse formation with CAR T cell effectiveness.66Xiong W. Chen Y. Kang X. Chen Z. Zheng P. Hsu Y.H. Jang J.H. Qin L. Liu H. Dotti G. Liu D. Immunological synapse predicts effectiveness of chimeric antigen receptor cells.Mol. Ther. 2018; 26: 963-975Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar,67Davenport A.J. Cross R.S. Watson K.A. Liao Y. Shi W. Prince H.M. Beavis P.A. Trapani J.A. Kershaw M.H. Ritchie D.S. et al.Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.Proc. Natl. Acad. Sci. USA. 2018; 115: E2068-E2076Crossref PubMed Scopus (69) Google Scholar Lastly, several studies have highlighted limit